Literature DB >> 27986516

Effects of withdrawal from repeated phencyclidine administration on behavioural function and brain arginine metabolism in rats.

Logan T Knox1, Yu Jing1, Jamal Bawazier-Edgecombe1, Nicola D Collie1, Hu Zhang2, Ping Liu3.   

Abstract

Phencyclidine (PCP) induces behavioural changes in humans and laboratory animals that resemble positive and negative symptoms, and cognitive impairments in schizophrenia. It has been shown repeated treatment of PCP leading to persistent symptoms even after the drug discontinuation, and there is a growing body of evidence implicating altered arginine metabolism in the pathogenesis of schizophrenia. The present study investigated the effects of withdrawal from repeated daily injection of PCP (2mg/kg) for 12 consecutive days on animals'behavioural performance and arginine metabolism in the hippocampus and prefrontal cortex in male young adult rats. Repeated PCP treatment reduced spontaneous alternations in the Y-maze and exploratory and locomotor activities in the open field under the condition of a washout period of 24h, but not 4days. Interestingly, the PCP treated rats also displayed spatial working memory deficits when tested 8-10days after withdrawal from PCP and showed altered levels of arginase activities and eight out of ten l-arginine metabolites in neurochemical- and region-specific manner. Cluster analyses showed altered relationships among l-arginine and its three main metabolites as a function of withdrawal from repeated PCP treatment in a duration-specific manner. Multiple regression analysis revealed significant neurochemical-behavioural correlations. Collectively, the results suggest both the residual and long-term effects of withdrawal from repeated PCP treatment on behavioural function and brain arginine metabolism. These findings demonstrate, for the first time, the influence of the withdrawal duration on animals' behaviour and brain arginine metabolism.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Arginine metabolism; Hippocampus; Phencyclidine; Prefrontal cortex; Rat; Schizophrenia

Mesh:

Substances:

Year:  2016        PMID: 27986516     DOI: 10.1016/j.pbb.2016.12.006

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Altered plasma arginine metabolome precedes behavioural and brain arginine metabolomic profile changes in the APPswe/PS1ΔE9 mouse model of Alzheimer's disease.

Authors:  D H Bergin; Y Jing; B G Mockett; H Zhang; W C Abraham; P Liu
Journal:  Transl Psychiatry       Date:  2018-05-25       Impact factor: 6.222

Review 2.  Polyamines and polyamine-metabolizing enzymes in schizophrenia: Current knowledge and concepts of therapy.

Authors:  Hans-Gert Bernstein; Gerburg Keilhoff; Gregor Laube; Henrik Dobrowolny; Johann Steiner
Journal:  World J Psychiatry       Date:  2021-12-19

3.  NX210c Peptide Promotes Glutamatergic Receptor-Mediated Synaptic Transmission and Signaling in the Mouse Central Nervous System.

Authors:  Sighild Lemarchant; Mélissa Sourioux; Juliette Le Douce; Alexandre Henriques; Noëlle Callizot; Sandrine Hugues; Mélissa Farinelli; Yann Godfrin
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.